Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of AZR-MD-001 in Meibomian Gland Dysfunction
NCT04391959Phase 2Completed
- Sponsor
- Azura Ophthalmics
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in meibomian gland dysfunction (MGD) comparing AZR-MD-001 Active with AZR-MD-001 Vehicle (2 arms). Primary endpoint: Meibum Gland Secretion Score at Month 3. Started Jul 2020; status: completed.
02
Drugs
selenium sulfide ophthalmic ointment
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT04391959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391959.